Intended for licensed healthcare professionals located in the EU.
Summary of Product Characteristics – EU
ICLUSIG
home
ICLUSIG
patient profiles
View expert videos
on ICLUSIG
ICLUSIG
resources
Because Tomorrows Matters Today
Blue square
Resources for ICLUSIG

Learn more about the treatment
for CML and Ph+ ALL

ICLUSIG has been with you since 2013. With over a decade of combined experience and data, we've built confidence that ICLUSIG may improve patients' futures.1–3
Video intro icon

DISCOVERY OF ICLUSIG

Play the video below to learn more about the key milestones of ICLUSIG and discover the progress made since 2013 in treating patients with CML and Ph+ ALL.

10-year icon

ICLUSIG HERITAGE INFOGRAPHIC

Want to discover more about the combined experience and data with ICLUSIG? Click through the concise and informative ICLUSIG infographic below.

Watch a series of short videos
where experts tell the ICLUSIG story
Click here

Abbreviations: CML, chronic myeloid leukaemia; Ph+ ALL, Philadelphia chromosome-positive acute lymphoblastic leukaemia.

References: 1. Cortes JE, et al. Blood. 2018;132:393–404; 2. Cortes J, et al. Blood. 2021;138:2042–50; 3. Cortes JE, et al. Poster presented at ASH 2023; Abstract 3164.

Privacy Policy Cookie Policy Terms of Use

EU/ICLG/P/24/0013
Date of preparation: July 2024

© 2025, Incyte. All rights reserved.
Marketing authorisation holder: Incyte Biosciences Distribution B.V.
ICLUSIG, the ICLUSIG logo and the Incyte logo are registered trademarks of Incyte.

If you would like to request further medical information, please visit:
www.incyteglobalmedicalinformation.com